Form 8-K Viridian Therapeutics, For: Sep 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Viridian Therapeutic (VRDN) PT Raised to $44 at RBC Capital
September 13, 2024 6:33 AM EDTRBC Capital analyst Gregory Renza raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $44.00 (from $35.00) while maintaining a Outperform rating.
The analyst comments "This week's pivotal ph.III THRIVE topline for veligrotug (Veli'; VRDN-001 IV) in active TED came in as a... More
